Stocks · News reference
Fractyl Health released findings from a market survey indicating significant patient interest in a one-time procedural approach for weight maintenance following GLP-1 therapy.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Fractyl Health is sharpening its focus on its lead product candidate, Revita, while discontinuing its Rejuva gene therapy program and reducing its workforce by approximately 45%.
Fractyl Health has appointed Harith Rajagopalan as president following the retirement of Jay Caplan.